$NVO
Novo Nordisk1/10Does he own it?
No first-person position language about NVO anywhere — no buying, holding, adding, or sizing. Every NVO mention is contextual to his actual trade, HIMS (as litigant, then partner). He even lumps NVO with other value/dividend names he deliberately avoided in favor of semis.
His thesis
NVO is never the analytical subject. It appears only as a force acting on HIMS: first an antagonist (lawsuit, pharma lobbying threatening to bankrupt HIMS), then a de-risking catalyst when it reportedly dropped the suit and partnered with HIMS, fueling his short-squeeze thesis. In his final mention he frames NVO as a stale value/dividend stock that underperformed semis this cycle — mildly dismissive rather than a position view.
How his view evolved
Shifts from casting NVO as a regulatory/legal threat to HIMS, to treating its HIMS partnership as a bullish de-risk event, to finally dismissing NVO as an extinct value/dividend play he avoided versus semis.
Key points
- NVO discussed only as context for his actual HIMS short-squeeze trade, never on its own merits
- No position statements, weight, or buy/hold language for NVO
- Final mention groups NVO with PYPL/FISV as underperforming value/dividend names he sidestepped
Derived from a holistic read of his public posts — paraphrased, never quoted. See his actual posts about $NVO on X ↗